# David W. Dodick

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/david-w-dodick/

## Facts

| Field | Value |
| --- | --- |
| Citations | 43,400 |
| Field | Migraine and Headache Studies |
| h-index | 105 |
| i10-index | 420 |
| Last Known Institution | New York Academy of Medicine |
| OpenAlex ID | https://openalex.org/A5057290642 |
| ORCID iD | 0000-0002-9486-6790 |
| Works | 834 |

## Researcher papers

Showing 12 of 17.

- [OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program](https://scholariq.org/papers/onabotulinumtoxina-for-treatment-of-chronic-migraine-pooled-results-from-the/)
- [Narrative Review: Reversible Cerebral Vasoconstriction Syndromes](https://scholariq.org/papers/narrative-review-reversible-cerebral-vasoconstriction-syndromes/)
- [New Appendix Criteria Open for a Broader Concept of Chronic Migraine](https://scholariq.org/papers/new-appendix-criteria-open-for-a-broader-concept-of-chronic-migraine/)
- [Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults](https://scholariq.org/papers/evidence-based-guideline-update-pharmacologic-treatment-for-episodic-migraine/)
- [A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease](https://scholariq.org/papers/a-randomized-trial-of-plasma-exchange-in-acute-central-nervous-system/)
- [Fremanezumab for the Preventive Treatment of Chronic Migraine](https://scholariq.org/papers/fremanezumab-for-the-preventive-treatment-of-chronic-migraine/)
- [A self-administered screener for migraine in primary care](https://scholariq.org/papers/a-self-administered-screener-for-migraine-in-primary-care/)
- [ARISE: A Phase 3 randomized trial of erenumab for episodic migraine](https://scholariq.org/papers/arise-a-phase-3-randomized-trial-of-erenumab-for-episodic-migraine/)
- [Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine](https://scholariq.org/papers/effect-of-fremanezumab-compared-with-placebo-for-prevention-of-episodic-migraine/)
- [Evaluation of Galcanezumab for the Prevention of Episodic Migraine](https://scholariq.org/papers/evaluation-of-galcanezumab-for-the-prevention-of-episodic-migraine/)
- [Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial](https://scholariq.org/papers/efficacy-and-tolerability-of-mk-0974-telcagepant-a-new-oral-antagonist-of/)
- [Comorbid and co-occurring conditions in migraine and associated risk of increasing headache pain intensity and headache frequency: results of the migraine in America symptoms and treatment (MAST) study](https://scholariq.org/papers/comorbid-and-co-occurring-conditions-in-migraine-and-associated-risk-of/)

## Researcher topics

- [Migraine and Headache Studies](https://scholariq.org/topics/migraine-and-headache-studies/)
- [Trigeminal Neuralgia and Treatments](https://scholariq.org/topics/trigeminal-neuralgia-and-treatments/)
- [Traumatic Brain Injury Research](https://scholariq.org/topics/traumatic-brain-injury-research/)
- [Sympathectomy and Hyperhidrosis Treatments](https://scholariq.org/topics/sympathectomy-and-hyperhidrosis-treatments/)
- [Neurological Complications and Syndromes](https://scholariq.org/topics/neurological-complications-and-syndromes/)

## Researcher university

- [New York Academy of Medicine](https://scholariq.org/institutions/new-york-academy-of-medicine/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.